Keywords: مهارکننده DPP-4; Albuminuria; DPP-4 inhibitor; Kidney; Renal failure; SGLT2 inhibitor; Type 2 diabetes;
مقالات ISI مهارکننده DPP-4 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده DPP-4; ATP; Adenosine 5c-triphosphate; ALT; Alanine aminotransferase; aa; Amino acid; ASK1; Apoptosis signal- regulating kinase 1; AST; Aspartate aminotransferase; BASH; Both alcoholic and non-alcoholic liver disease; CCR2/CCR5; C-C chemokine receptor types 2 an
Keywords: مهارکننده DPP-4; Drug-induced lung injury; DPP-4 inhibitor; VildagliptinBAL, bronchoalveolar lavage; CT, computed tomography; DLST, drug lymphocyte stimulation tests; DPP-4, dipeptideylpeptidase-4; FVC, forced vital capacity; IgE, immunoglobulin E; IPAF, interstitial pneu
Keywords: مهارکننده DPP-4; Wound healing; Insulin; Metformin; Sulfonylurea; Thiazolidinedione; DPP-4 inhibitor;
Keywords: مهارکننده DPP-4; Type 2 diabetes; Metformin; Sulfonylurea; Insulin; GLP-1 analog; DPP-4 inhibitor; SGLT-2 inhibitor;
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Type 2 diabetes; Liver disease; Pooled analysis; Efficacy; Safety;
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Type 2 diabetes; DPP-8; DPP-9; Sitagliptin; Pyrazolopyrolidine; Omarigliptin; X-ray;
Keywords: مهارکننده DPP-4; Type 2 diabetes; DPP-4 inhibitor; Sitagliptin; Fatty liver; Body fat;
Keywords: مهارکننده DPP-4; GLP-1 agonist; DPP-4 inhibitor; heart failure; outcomes
Keywords: مهارکننده DPP-4; Non-alcoholic steatohepatitis (NASH); Sitagliptin; MCD diet; GLP-1; DPP-4 inhibitor;
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Ischemia-reperfusion injury; Mitochondria; Electrophysiology; Infarct size;
Keywords: مهارکننده DPP-4; diabetes; DPP-4 inhibitor; drug-drug interaction; empagliflozin; linagliptin; SGLT2 inhibitor;
Keywords: مهارکننده DPP-4; cardiovascular risk; DPP-4 inhibitor; insulin; linagliptin; type 2 diabetes mellitusrisque cardiovasculaire; inhibiteur de la DPP-4; insuline; linagliptine; diabète sucré de type 2
Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes
Keywords: مهارکننده DPP-4; TGR5; TGR5 agonist; GPBAR1; GLP1 secretion; Type 2 diabetes; Sitagliptin; DPP-4 inhibitor;
Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors
Keywords: مهارکننده DPP-4; Pyrimidinedionederivatives; DPP-4 inhibitor; Molecular hybrid; SARs; Type 2 diabetes;
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Sitagliptin; Inflammation; Retinal endothelial cells; Endothelial permeability; Angiogenesis; Migration;
Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future
Keywords: مهارکننده DPP-4; Type 1 diabetes mellitus; LADA; DPP-4 inhibitor; Vitamin D3;
Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives; Structure-based drug design; Molecular docking; Anti-diabetic;
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Incretin therapy; Omarigliptin; Patient non-adherence; Prohibited medication; Protocol violation;
Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors
Keywords: مهارکننده DPP-4; T2DM; DPP-4 inhibitor; Uracil derivatives; Triazole; Amide;
Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Type 2 diabetes; SAR; Long-acting; In vivo efficacy;
A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats
Keywords: مهارکننده DPP-4; DPP-4; dipeptidyl peptidase-4; GLP-1; glucagon-like peptide-1; ·OH; hydroxyl-radical; O2â; superoxide; ESR; electron spin resonance; 8-OHdG; 8-hydroxy-2â²-deoxyguanosine; XOD; xanthine oxidase; DMPO; 5.5-dimethyl-l-pyrroline-N-oxide; HPX; hypoxanthine
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
Keywords: مهارکننده DPP-4; DIO; diet-induced obese; DPP; dipeptidyl peptidase; FAS; fatty acid synthase; FPG; fasting plasma glucose; GDR; glucose disposal rate; HbA1c; glycated hemoglobin; HGP; hepatic glucose production; HPRT; hypoxanthine phosphoribosyltransferase; OGTT; oral gl
Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Angiogenesis; Myocardium; Diabetes; Strenuous exercise;
Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice
Keywords: مهارکننده DPP-4; Mosapride; 5-HT4 receptor agonist; Alogliptin; DPP-4 inhibitor; GLP-1; Glucose tolerance
Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes
Keywords: مهارکننده DPP-4; ABC transporters; Adipocytes; Cholesterol; DPP-4 inhibitor; GLP-1;
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; CD4+ T cell; T-helper 17 cell; Regulatory T cell
Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Observational study; Type 2 diabetes
Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression
Keywords: مهارکننده DPP-4; Thiazolidine derivative; DPP-4 inhibitor; Pancreatic β-cells; Cellular kineticsPio, pioglitazone; Alo, alogliptin; GSIS, glucose-stimulated insulin secretion; IPITT, intraperitoneal glucose tolerance test; PPARγ, peroxisome proliferator-activated receptor
Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Morris water maze; Oxidative stress; Attentional-set shifting; Blood brain barrier;
Modulación del efecto incretina en el tratamiento de la diabetesModulation of the incretin effect in the treatment of diabetes
Keywords: مهارکننده DPP-4; Análogo GLP-1; Análogo receptor GLP-1; Diabetes; GIP; GLP-1; Glucagón; Incretina; Inhibidor DPP-4; Vaciamiento gástrico; GLP-1 analog; GLP-1 analog receptor; Diabetes; GIP; GLP-1; Glucagon; Incretin; DPP-4 inhibitor; Gastric emptying;
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Immune function; Side effects; Type 2 diabetes;
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Linagliptin; High fat diet; MCAO; Stroke; GLP-1
Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; HbA1c; linagliptin; type 2 diabetes mellitus;
The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Sitagliptin; Hypertension; Cardiomyocytes; Calcium handling;
Research ReportAlogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice
Keywords: مهارکننده DPP-4; Neuroprotection; Focal ischemia; Neurotrophic factor; DPP-4 inhibitor; Ischemic stroke; Preclinical study;
A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Type 2 diabetes mellitus; Pancreatic amylase; Lipase; Pancreatitis
Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials
Keywords: مهارکننده DPP-4; Combination therapy; DPP-4 inhibitor; Linagliptin; Poor glycemic control; Type 2 diabetes mellitus
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes ★
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; sitagliptin; glycemic control; hyperglycemia; hemoglobin A1c
The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Exercise; Pre-diabetes; Kkay mice; MafA; PDX-1; Proliferation
New Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats
Keywords: مهارکننده DPP-4; Cat; Feline; Diabetes mellitus; GLP-1 receptor agonist; DPP-4 inhibitor; Exenatide; Sitagliptin;
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Type 2 diabetes
Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; GLP-1 receptor agonist; Incretin; Sitagliptin; Exenatide; Liraglutide
Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Thiazolidine; Bicyclic heteroarylpiperazine
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Thiazolidine; Bicyclic heteroarylpiperazine;
Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Keywords: مهارکننده DPP-4; Dipeptidyl peptidase-IV; DPP-IV; DPP-4; GLP-1; DPP-4 inhibitor; DA-1229
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Incretins; Glycemic control; Metformin; Saxagliptin
A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects
Keywords: مهارکننده DPP-4; bioavailability; DPP-4 inhibitor; food; linagliptin; pharmacokinetics; type 2 diabetes
Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes
Keywords: مهارکننده DPP-4; DPP-4 inhibitor; Aza-bicyclo[3.2.0]heptane scaffold; 2-Cyano pyrrolidine alpha-amino amide derivative; Synthesis; Type 2 diabetes
Unraveling the Science of Incretin Biology ✩
Keywords: مهارکننده DPP-4; GLP-1 receptor agonist; DPP-4 inhibitor; liraglutide; exenatide; sitagliptin; vildagliptin